

# Corrigendum to “Differentiation-dependent repression of *c-myc*, *B22*, *COX II* and *COX IV* genes in murine erythroleukemia (MEL) cells” [Biochem. Pharmacol. 63 (2002) 1009–1017]<sup>☆</sup>

Ioannis S. Vizirianakis, Ioannis S. Pappas, Asterios S. Tsiftoglou<sup>\*</sup>

Laboratory of Pharmacology, Department of Pharmaceutical Sciences, Aristotle University of Thessaloniki, GR-540 06 Thessaloniki, Greece

It is regretted that in the above article a number of typographical errors were introduced and we apologise for any confusion this may have caused readers. The correct text and table are reproduced below.

From page 6, left column, 1st paragraph, 6th sentence:

In these cultures, the steady state level of  $\beta$ -actin mRNA declined only after 48–60 hr in culture (Figs. 1G and L and 2F and J), when a large proportion of MEL cells exposed (about 60% after 48 hr, [Table 1](#)) had been committed to differentiation, an effect reported earlier by others [17].

Table 1

Cell growth and differentiation of MEL cells exposed either to DMSO in the absence or presence of  $N^6$ mAdo, or to UDP-4<sup>a</sup>

Time (hr)	Treatment	Concentration (M)	Cell growth (cells/mL)	Benzidine-positive cells (% of control)
48	None	–	$7.0 \times 10^5$	<1
	UDP-4	$2.5 \times 10^{-4}$	$5.5 \times 10^5$	64.5
	DMSO	0.210	$9.8 \times 10^5$	54.2
	DMSO + $N^6$ mAdo	$0.210 + 5 \times 10^{-4}$	$2.9 \times 10^5$	14.0
72	None	–	$3.3 \times 10^6$	<1
	UDP-4	$2.5 \times 10^{-4}$	$9.8 \times 10^5$	94.6
	DMSO	0.210	$1.6 \times 10^6$	86.0
	DMSO + $N^6$ mAdo	$0.210 + 5 \times 10^{-4}$	$8.2 \times 10^5$	25.6
96	None	–	$3.4 \times 10^6$	<1
	UDP-4	$2.5 \times 10^{-4}$	$1.0 \times 10^6$	95.2
	DMSO	0.210	$1.7 \times 10^6$	96.4
	DMSO + $N^6$ mAdo	$0.210 + 5 \times 10^{-4}$	$1.5 \times 10^6$	31.4

<sup>a</sup> MEL-745PC-4A cells ( $8 \times 10^4$  cells/mL) were incubated separately with UDP-4 or DMSO in the absence or presence of  $N^6$ mAdo at the concentrations indicated. Cell growth and the proportion of differentiated cells were determined at 48, 72 and 96 hr as previously reported [12–14].

<sup>☆</sup> PII of original article: S0006-2952(01)00937-6

<sup>\*</sup> Corresponding author. Tel.: +30-31-997-631; fax: +30-31-997-618.

E-mail address: tsif@pharm.auth.gr (A.S. Tsiftoglou).